The purpose of this study is to investigate experimental medication BMS-986278 given to healthy participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
112
Specified dose on specified days
Specified dose on specified days
Local Institution
Groningen, Netherlands
Local Institution
London, United Kingdom
Number of participants experiencing adverse events (AE), serious adverse events (SAE), death, or an AE leading to study discontinuation
Time frame: Up to 30 days
Number of participants with potentially clinically significant changes in ECG parameters, vital signs, clinical laboratory parameters, or physical examinations
Time frame: Up to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.